Skip to main
  1. Stocks
  2. DarioHealth
  3. Forecast
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is attractive fundamentally because it combines FDA-cleared connected hardware, evidence-backed clinical programs, and AI trained on 13B+ proprietary data points, creating a hard-to-replicate platform with stronger personalization, engagement, and outcomes than software-only peers. Its commercial base is broad and still expanding, with 180+ enterprise customers, 25% from Fortune 500 companies, access to more than 175M lives, and 85 new clients added in 2025, while over 80% of ARR already comes from multi-condition sales. Despite near-term revenue pressure from the bio-pharma transition and a large legacy account roll-off, the business has ~$13.1M of contracted and late-stage ARR, 62% gross margin in 2Q:26, 90% client retention, and management expects AI and new wins to support improving revenue and cash flow.

Bears say

DarioHealth is facing a fundamentally difficult setup marked by intense competition in crowded employer and payer channels, where it must compete against both point solutions and shifting benefit budgets, limiting visibility into sustained share gains. Its latest results underscore the strain: 2Q revenue of $5.2M missed estimates, adjusted EBITDA loss was ($5.3M), and management’s lack of formal guidance, alongside revised 2026/2027 revenue and EBITDA estimates, signals an uncertain path to profitability. That uncertainty is compounded by roughly $31M of debt versus about $7M of cash at 2Q:26, continued execution risk in converting $13M of new contracted ARR, and the possibility that weak demand, churn, or further dilutive financing could pressure the stock.

DarioHealth (DRIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

DarioHealth (DRIO) Analyst Forecast & Price Prediction

Get the latest DarioHealth (DRIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DarioHealth (DRIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 4 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


DarioHealth (DRIO) Analyst Forecast & Price Prediction

Get the latest DarioHealth (DRIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DarioHealth (DRIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DRIO stock data and trends